Truist analyst Srikripa Devarakonda lowered the firm’s price target on Keros Therapeutics (KROS) to $43 from $100 and keeps a Buy rating on the shares. Keros recently announced updates to their lead programs, including a global partnership with Takeda (TAK) for the development and commercialization of anemia drug elritercept, which the firm saw as a positive, as well as a more recent update around safety concerns with second lead asset cibotercept following observation of pericardial effusion in the ongoing Phase 2 study, which led to a significant pullback in the stock, the analyst tells investors. While the firm has updated its model to reflect these recent developments and believes the reaction to the PAH news was “excessive,” it also believes the stock could trade sideways near-term, the analyst noted.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics price target lowered to $63 from $102 at Oppenheimer
- Keros Therapeutics downgraded to Neutral from Buy at Guggenheim
- Keros Therapeutics price target lowered to $44 from $77 at Scotiabank
- Keros Therapeutics price target raised to $28 from $11 at Wells Fargo
- Keros Therapeutics price target lowered to $47 from $100 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
